Focuses on developing drugs that target the mitochondria for a host of serious diseases.

Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. The company’s development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies.

Industry: Health
Status: Active

Contact Information

http://www.mitochonpharma.com/

ralonso@mitochonpharma.com

Robert Alonso

CEO

John Geisler

CSO

Peter Crooks

SVP of Chemistry

Ph.D.